EVOLVA HOLDING SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.91 CHF | -1.09% |
|
-0.22% | +26.39% |
| Apr. 15 | Evolva Shareholders Pass Resolutions to Revoke Liquidation, Delisting | MT |
| Mar. 26 | Evolva Secures Temporary Exemption from Listing Rules Amid Liquidation | MT |
| Sales 2022 | 15.54M 17.34M | Sales 2023 | 4.16M 4.64M | Capitalization | 4.9M 5.47M |
|---|---|---|---|---|---|
| Net income 2022 | -43M -47.98M | Net income 2023 | -101M -113M | EV / Sales 2022 | 6.5 x |
| Net Debt 2022 | 9.91M 11.06M | Net cash position 2023 | 5.84M 6.51M | EV / Sales 2023 | -0.23 x |
| P/E ratio 2022 |
-2.02
x | P/E ratio 2023 |
-0.05
x | Employees | 49 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Evolva Holding SA
More recommendations
More press releases
More news
| 1 day | -1.09% | ||
| 1 week | -0.22% | ||
| 1 month | -2.57% | ||
| 3 months | -14.95% | ||
| 6 months | +27.81% | ||
| Current year | +26.39% |
1 week
0.89
0.96
1 month
0.890.99
Current year
0.621.09
1 year
0.625.06
3 years
0.6246.05
5 years
0.6293.50
10 years
0.62465.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 22-02-07 | |
Gerhard Lobmaier
COO | Chief Operating Officer | 55 | 20-12-31 |
Astrid Schäfer
CTO | Chief Tech/Sci/R&D Officer | 51 | 17-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 60 | 20-04-14 | |
Beat In-Albon
BRD | Director/Board Member | 72 | 20-04-14 |
Andreas Pfluger
BRD | Director/Board Member | 64 | 22-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-05 | 0.91 | -1.09% | 440 |
| 24-07-04 | 0.92 | +1.10% | 1,259 |
| 24-07-03 | 0.91 | +1.56% | 586 |
| 24-07-02 | 0.896 | -5.49% | 922 |
| 24-07-01 | 0.948 | +4.18% | 11,722 |
Delayed Quote Swiss Exchange, July 05, 2024 at 11:31 am EDT
More quotes
Evolva Holding SA (Evolva) discovers and provides ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to create small molecule compounds and their production routes. The Companyâs nutrition and consumer products include Pomecins, saffron, stevia, vanilla and resveratrol. The Companyâs pharmaceuticals products include EV-077 and EV-035. In pharmaceuticals, the Company focuses on oral, small molecule drugs with application in complications of diabetes and infectious diseases. Pomecins are Evolvaâs compounds. Evolva is focused on two members of the family - Pomecin A and Pomecin B. EV-035 is a bacterial type II topoisomerase inhibitor. Evolva is developing EV-077 for the treatment of diabetic complications. It is an oral, small molecule compound, belonging to a structural class.
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +26.39% | 7.37M | |
| +18.97% | 44.44B | |
| +41.98% | 40.03B | |
| -10.06% | 37.68B | |
| +31.15% | 31.46B | |
| -7.79% | 27.29B | |
| +13.32% | 26.29B | |
| +43.05% | 13.8B | |
| +31.28% | 12.46B | |
| -7.41% | 11.26B |
- Stock Market
- Equities
- EVE Stock
